Birch triterpenes by Chiesi Farmaceutici for Radiodermatitis: Likelihood of Approval

Birch triterpenes is under clinical development by Chiesi Farmaceutici and currently in Phase II for Radiodermatitis.

At this year’s ObesityWeek, GLP-1s aren’t the only talk of the town

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

November 7, 2024

Insmed stock skyrockets on Phase 3 lung disease data

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

May 29, 2024

Medicare spells out what the new Alzheimer’s drug registries will collect

As part of efforts to improve access to drugs that may slow the progression of Alzheimer’s disease, Medicare reiterated that it will cover new anti-amyloid

June 24, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.